Population-based analysis of non-steroidal anti-inflammatory drug use among children in four European countries in the SOS project: What size of data platforms and which study designs do we need to assess safety issues?

BMC Pediatrics

Volumn 13, Issue 1, 2013, Pages

  Valkhoff, Vera E ^a   Schade, René ^a   't Jong, Geert W ^a,b,c   Romio, Silvana ^a,d   Schuemie, Martijn J ^a   Arfe, Andrea ^d   Garbe, Edeltraut ^e   Herings, Ron ^f   Lucchi, Silvia ^g   Picelli, Gino ^h   Schink, Tania ^e   Straatman, Huub ^f   Villa, Marco ^g   Kuipers, Ernst J ^a   Sturkenboom, Miriam C J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

^e LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

^f PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^g Local Health Unit of Cremona   (Italy)

^h International Pharmacoepidemiology and Pharmacoeconomics Research Center   (Italy)

Author keywords

Asthma exacerbation; Case crossover design; Database; Drug safety; Drug utilization; Health resource utilization; Pharmacoepidemiology; Sample size; Self controlled case series design

Indexed keywords

CELECOXIB; DICLOFENAC; ETODOLAC; ETORICOXIB; FENBUFEN; FENOPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; LONAZOLAC; MEFENAMIC ACID; MELOXICAM; MISOPROSTOL; MORNIFLUMATE; NAPROXEN; NIFLUMIC ACID; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PIROXICAM; ROFECOXIB;

ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ACUTE LIVER FAILURE; ADOLESCENT; ADULT; ANAPHYLACTIC SHOCK; ARTICLE; ASTHMA; CEREBROVASCULAR ACCIDENT; CHILD; DISEASE EXACERBATION; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; DRUG UTILIZATION; EUROPE; FEMALE; GASTROINTESTINAL DISEASE; GERMANY; HEART FAILURE; HUMAN; INCIDENCE; INFANT; ITALY; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NEWBORN; PATIENT CODING; POPULATION; PRESCHOOL CHILD; PRESCRIPTION; PREVALENCE; REYE SYNDROME; RISK FACTOR; SCHOOL CHILD; STEVENS JOHNSON SYNDROME; STUDY DESIGN; UNITED KINGDOM; UPPER GASTROINTESTINAL COMPLICATION; YOUNG ADULT;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CHILD, PRESCHOOL; DATABASES, PHARMACEUTICAL; DRUG UTILIZATION; EUROPE; FEMALE; HUMANS; INFANT; LONGITUDINAL STUDIES; MALE; PATIENT SAFETY; PHARMACOEPIDEMIOLOGY; RESEARCH DESIGN; RISK;

EID: 84887647359     PISSN: None     EISSN: 14712431     Source Type: Journal    
DOI: 10.1186/1471-2431-13-192     Document Type: Article

References (34)

1. Sturkenboom MC, Verhamme KM, Nicolosi A, Murray ML, Neubert A, Caudri D, Picelli G, Sen EF, Giaquinto C, Cantarutti L, et al. Drug use in children: cohort study in three European countries. BMJ 2008, 337:a2245. 10.1136/bmj.a2245, 2593449, 19029175.
2. Salvo F, Fourrier-Reglat A, Bazin F, Robinson P, Riera-Guardia N, Haag M, Caputi AP, Moore N, Sturkenboom MC, Pariente A. Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials. Clin Pharmacol Ther 2011, 89:855-866. 10.1038/clpt.2011.45, 21471964.
3. Assessment of the paediatric needs, pain. Paediatric working party of the european medicines agency. 2005, Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/10/WC500004037.pdf (accessed April 4, 2012).
4. World Health Organization Classification of Diseases. Available at: http://www.who.int/classifications/icd/en/. (accessed April 4, 2011), World Health Organization.
5. WHO collaborating centre for drug statistics methodology. Guidelines for ATC classification and DDD assignment. Available at: http://www.whocc.no/atcddd/. (accessed April 4, 2012).
6. Lamberts H, Wood M, Hofmans-Okkes IM. International primary care classifications: the effect of fifteen years of evolution. Fam Pract 1992, 9:330-339. 10.1093/fampra/9.3.330, 1459391.
7. Coloma PM, Schuemie MJ, Trifiro G, Gini R, Herings R, Hippisley-Cox J, Mazzaglia G, Giaquinto C, Corrao G, Pedersen L, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf 2011, 20:1-11. 10.1002/pds.2053, 21182150.
8. Ashraf E, Ford L, Geetha R, Cooper S. Safety profile of ibuprofen suspension in young children. Inflammopharmacology 1999, 7:219-225. 10.1007/s10787-999-0005-0, 17638093.
9. Lesko SM, Louik C, Vezina RM, Mitchell AA. Asthma morbidity after the short-term use of ibuprofen in children. Pediatrics 2002, 109:E20. 10.1542/peds.109.2.e20, 11826230.
10. Lesko SM, Mitchell AA. An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial. JAMA 1995, 273:929-933. 10.1001/jama.1995.03520360043037, 7884951.
11. Lesko SM, Mitchell AA. Renal function after short-term ibuprofen use in infants and children. Pediatrics 1997, 100:954-957. 10.1542/peds.100.6.954, 9374563.
12. Lesko SM, Mitchell AA. The safety of acetaminophen and ibuprofen among children younger than two years old. Pediatrics 1999, 104:e39. 10.1542/peds.104.4.e39, 10506264.
13. Pierce CA, Voss B. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review. Ann Pharmacother 2010, 44:489-506. 10.1345/aph.1M332, 20150507.
14. Southey ER, Soares-Weiser K, Kleijnen J. Systematic review and meta-analysis of the clinical safety and tolerability of ibuprofen compared with paracetamol in paediatric pain and fever. Curr Med Res Opin 2009, 25:2207-2222. 10.1185/03007990903116255, 19606950.
15. Sullivan JE, Farrar HC. Fever and antipyretic use in children. Pediatrics 2011, 127:580-587. 10.1542/peds.2010-3852, 21357332.
16. Ulinski T, Guigonis V, Dunan O, Bensman A. Acute renal failure after treatment with non-steroidal anti-inflammatory drugs. Eur J Pediatr 2004, 163:148-150. 10.1007/s00431-003-1392-7, 14745553.
17. Unified Medical Language System® (UMLS®) from the U.S. National Library of Medicine. Available at: http://www.nlm.nih.gov/research/umls/. (accessed April 4, 2011).
18. Avillach P, Mougin F, Joubert M, Thiessard F, Pariente A, Dufour JC, Trifiro G, Polimeni G, Catania MA, Giaquinto C, et al. A semantic approach for the homogeneous identification of events in eight patient databases: a contribution to the European eu-ADR project. Stud Health Technol Inform 2009, 150:190-194.
19. World Health Organization WHO standard population. 2001, Available at: http://www.who.int/healthinfo/paper31.pdf. (accessed April 4, 2012), World Health Organization.
20. Coloma PM, Trifiro G, Schuemie MJ, Gini R, Herings R, Hippisley-Cox J, Mazzaglia G, Picelli G, Corrao G, Pedersen L, et al. Electronic healthcare databases for active drug safety surveillance: is there enough leverage?. Pharmacoepidemiol Drug Saf 2012, 21:611-621. 10.1002/pds.3197, 22315152.
21. National Collaborating Centre for Women's and Children's Health Feverish illness in children. Assessment and initial management in children younger than 5 years 2007, London: National Institute for Health and Clinical Excellence, National Collaborating Centre for Women's and Children's Health.
22. Kindern FB. Patientenleitlinien.de. Universität Witten-Herdecke. 2006, Available at: http://www.patientenleitlinien.de/Fieber_Kindesalter/fieber_kindesalter.html (accessed April 4, 2012).
23. Chiappini E, Venturini E, Principi N, Longhi R, Tovo PA, Becherucci P, Bonsignori F, Esposito S, Festini F, Galli L, et al. Update of the 2009 Italian pediatric society guidelines about management of fever in children. Clin Ther 2012, 34:1648-1653. e1643, 10.1016/j.clinthera.2012.06.011, 22742886.
24. Berger M, Boomsma L, Albeda F, Dijkstra R, Graafmans T, Van der Laan J, Lemmen W, Oteman N. NHG-Standaard Kinderen met koorts (Tweede herziening). Huisarts Wet 2008, 51:287-296.
25. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003, 158:915-920. 10.1093/aje/kwg231, 14585769.
26. Maclure M, Fireman B, Nelson JC, Hua W, Shoaibi A, Paredes A, Madigan D. When should case-only designs be used for safety monitoring of medical products?. Pharmacoepidemiol Drug Saf 2012, 21(Suppl 1):50-61.
27. Farrington CP, Nash J, Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol 1996, 143:1165-1173. 10.1093/oxfordjournals.aje.a008695, 8633607.
28. Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics 1995, 51:228-235. 10.2307/2533328, 7766778.
29. Whitaker HJ, Hocine MN, Farrington CP. The methodology of self-controlled case series studies. Stat Methods Med Res 2009, 18:7-26. 10.1177/0962280208092342, 18562396.
30. Farrington CP, Whitaker HJ, Hocine MN. Case series analysis for censored, perturbed, or curtailed post-event exposures. Biostatistics 2009, 10:3-16.
31. Farrington CP, Anaya-Izquierdo K, Whitaker H, Hocine MN, Douglas I, Smeeth L. Self-controlled case series analysis with event-dependent observation periods. J Am Stat Assoc 2011, 106(494):417-426.
32. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991, 133:144-153.
33. Suissa S. The case-time-control design. Epidemiology 1995, 6:248-253. 10.1097/00001648-199505000-00010, 7619931.
34. Wang S, Linkletter C, Maclure M, Dore D, Mor V, Buka S, Wellenius GA. Future cases as present controls to adjust for exposure trend bias in case-only studies. Epidemiology 2011, 22:568-574. 10.1097/EDE.0b013e31821d09cd, 3110688, 21577117.